CA
NZ
UK
AU
IND
US
Imunon, Inc. (NASDAQ:IMNN) is running a 500-patient pivotal cancer trial while carrying a stockMarket ValueStockTitan listed at roughly $6.8 million in mid-August 2026. That gap came into focus on 11 August, when the New Jersey biotech reported second-quarter results and filed its quarterly report.
Nexalin Technology, Inc. (NASDAQ:NXL) has produced the clinical headlines a small neurotechnology developer wants in 2026: a 77.8% anxiety response rate from a Brazilian trial, a new U.S. patent, and an FDA pivotal study now recruiting. Its shareholders have watched the stock slide to …
Revelation Biosciences, Inc. (NASDAQ:REVB) is a San Diego clinical-stage biotechnology company with eight full-time employees, noRevenueand under four million shares outstanding. On 10 July 2026 its board adopted a stockholder rights plan, the defensive structure known as a poison pill, triggered at just 10% …
SINTX Technologies, Inc. (NASDAQ:SINT) has spent 2026 fighting on two fronts: proving its silicon nitride ceramic can win commercial orders, and proving to Nasdaq that it belongs on the exchange. On 13 August the second fight ended in its favour.
Aprea Therapeutics, Inc. (NASDAQ:APRE) has spent 2026 doing something unusual for a micro-cap biotech: raising money, then immediately spending it on speed. Its second-quarter results, published on 12 August 2026, read less like a routine financial statement than a progress report on a deliberate …
Bionano Genomics, Inc. (NASDAQ:BNGO) has spent two years shrinking in order to survive. On 10 August 2026 the San Diego company reported second-quarter results showing the other side of that process: revenue growing again, grossMarginabove 50%, and no securedDebton the balance sheet.
Aclarion, Inc. (NASDAQ:ACON) has an unusual problem: an activist investor tried to buy the company for more than the market would pay, and the board said no. The ColoradoMedTechsells Nociscan, a magnetic resonance spectroscopy (MRS) test that reads chemical signals inside spinal discs to …
● Zentalis Pharmaceuticals shares fell roughly 6.5% in after-hours trading following a dilutive share offering.
● Prime Medicine is a Cambridge, Massachusetts-based gene-editing biotech built around Prime Editing, a precision DNA-rewriting technology.
● Rocket Pharmaceuticals is a commercial-stage gene-therapy company built around treatments for ultra-rare genetic diseases.
Please wait processing your request...